Sugi Predict

Sugi Predict / Compounds / SCHEMBL4085803

SCHEMBL4085803

SCHEMBL4085803

O=C(O)CCNC(=O)c1ccc(CN(CC(c2ccccc2)c2ccccc2)C(=O)/C=C/c2c(Cl)cccc2Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 7/20 0.52
▸ GLP1R P43220 1/20 0.52
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ POLB P06746 1/20 0.39
▸ GCG P01275 1/20 0.39
▸ TMEM97 Q5BJF2 3/20 0.38
▸ SIGMAR1 Q99720 3/20 0.38
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ EPHX2 P34913 1/20 0.37
▸ GLA P06280 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4085804 1.00 GCGR (0.52) GCGRGLP1RKMT2AMEN1POLB
SCHEMBL2662999 0.85 GCGR (0.47) GCGRGLP1RKMT2AMEN1TMEM97
SCHEMBL3538160 0.85 GCGR (0.47) GCGRGLP1RKMT2AMEN1TMEM97
SCHEMBL4094093 0.84 GCGR (0.42) GCGRGLP1RGCGTMEM97SIGMAR1
SCHEMBL2662959 0.84 GCGR (0.42) GCGRGLP1RGCGTMEM97SIGMAR1
SCHEMBL2663201 0.79 GCGR (0.53) GCGRGLP1RKMT2AGCGTMEM97
SCHEMBL4082131 0.79 L3MBTL1 (0.42) GCGRGCG
SCHEMBL4082128 0.79 L3MBTL1 (0.42) GCGRGCG
SCHEMBL13800474 0.78 GCGR (0.61) GCGRGLP1RTMEM97SIGMAR1EPHX2
SCHEMBL2663347 0.74 GCGR (0.56) GCGRGLP1RPOLBTMEM97SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed
WO-2000069810-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GLP1R 1/4885KMT2A 3304/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCGR 3/4885GLP1R 1/4885KMT2A 3304/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GLP1R 1/4885KMT2A 3304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.